Udit Batra is Chief Executive Oﬃcer of MilliporeSigma, the €6.2 billion Life Science business of Merck KGaA, Darmstadt, Germany, and a member of its Executive Board. In addition to leading MilliporeSigma, Udit has Board responsibility for the company's global Information Technology function. He also oversees the company's Bioethics Advisory Panel.
Born in New Delhi, India, Udit is an accomplished executive who has dedicated his career to improving health for people globally, bringing more than 20 years' experience in healthcare and the life sciences. After Udit became CEO in 2014, he and his team developed and executed a growth strategy that included the 2015 acquisition of chemicals and technology giant Sigma-Aldrich. Udit architected and led this merger — the largest acquisition in the company's history and one of the largest ever in the life science industry.
Today, Udit continues to lead the business through a strategic transformation that has made MilliporeSigma a top-three player in the industry and an employer of choice in many regions around the world.
MilliporeSigma, with a Life Science Center in Burlington, Massachusetts, was named to The Boston Globe's annual "Top Places to Work" list in 2016 and 2017, as well as the Boston Business Journal's "Best Places to Work" list in 2019. The company received an exclusive certiﬁcation as a top employer in North America by the independent Top Employers Institute in 2018 for the second year in a row. Also under Udit's leadership, MilliporeSigma has earned several prestigious awards for innovation, including a Life Science Industry Award by BioInformatics in 2016 and an R&D 100
Award for Corporate Responsibility in 2017.
Udit has earned a well-deserved reputation for driving business growth and turnarounds, as well as building high-performing teams. Previously, as head of the company’s global Consumer Health business, he and his team more than doubled the proﬁtability of the business, making it the fastest-growing sector within Merck KGaA, Darmstadt, Germany.
Earlier in his career, Udit served in a range of leadership positions at Novartis, a Swiss multinational pharmaceutical company. In addition to leading Corporate Strategy and Global Public Health and Market Access for Vaccines and Diagnostics, he also served as president of the Australia Pharma business. During his tenure, this subsidiary became the fastest-growing business within Novartis. Prior to that, Udit held senior positions in the healthcare, consumer, and non-proﬁt practices at McKinsey & Company, a global strategy, and consulting company.
Udit earned both a Ph.D. and a B.S. in chemical engineering from Princeton University and the University of Delaware, respectively. He started his career as a research engineer fellow at Merck & Co., Inc., Kenilworth, NJ, where he worked on vaccines and small molecules. He has received multiple honors and awards, including nationally competitive, recognized fellowships at Merck & Co.; DuPont and Mitsubishi. He serves on the boards of the Greater Boston Chamber of Commerce, Massachusetts Biotechnology Council and the Massachusetts High Technology Council, as chairman. He is also a member of the Advisory Council at Princeton University’s Department of Chemical Engineering and a member of the Advisory Council at the University of Delaware’s Department of Chemical Engineering.
In 2016, Udit was named "CEO of the Year" by CPhI Pharma
and was also recognized for his strategic leadership by PharmaVOICE 100
in its list of top inﬂuencers. Udit is a frequent keynote speaker, representing MilliporeSigma at global investor conferences and industry congresses. Most recently, he addressed the National Institute for Innovation in Manufacturing Biopharmaceuticals in Washington, DC; BioAsia in India; Societe de Chimie in New York, NY; University of Delaware’s Gerster Lecture and the Drug, Chemical & Associated Technologies Association, among others.